---
title: "Hookipa Pharma Sells Immuno-Oncology Assets to NeoTrail Therapeutics"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/274664850.md"
datetime: "2026-02-03T13:30:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274664850.md)
  - [en](https://longbridge.com/en/news/274664850.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274664850.md)
---

# Hookipa Pharma Sells Immuno-Oncology Assets to NeoTrail Therapeutics

HOOKIPA Pharma Inc. has announced the sale of its immuno-oncology assets, including the HB-200 and HB-700 development programs, to NeoTrail Therapeutics, Inc. The transaction was formalized on January 28, 2026, and is expected to close in the second quarter of 2026, pending customary closing conditions. The purchase price was not disclosed. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hookipa Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9647584) on February 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [512010.CN](https://longbridge.com/en/quote/512010.CN.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)

## Related News & Research

- [Palisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week (DDW) 2026 | PALI Stock News](https://longbridge.com/en/news/283003856.md)
- [Fate Therapeutics Details Off-the-Shelf CAR T Progress in Lupus and Solid Tumors at Needham Conference](https://longbridge.com/en/news/282940584.md)
- [Annual General Meeting 2026 Resolutions | SBFFF Stock News](https://longbridge.com/en/news/282875133.md)
- [CRISPR Therapeutics Touts “Second Phase” After Casgevy, Eyes 6 Data Readouts in 6–12 Months](https://longbridge.com/en/news/282582813.md)
- [Resverlogix Corp. Announces Filing of Annual Filings and Revocation of MCTO | RVXCF Stock News](https://longbridge.com/en/news/282988720.md)